Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.68 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6379526 | 1.00 | AR (0.68) | ARCTSBGAARAB9AAGTR2 | |
| SCHEMBL6375479 | 0.92 | AR (0.65) | ARCTSBALDH1A1 | |
| SCHEMBL4042253 | 0.92 | AR (0.65) | ARCTSBALDH1A1 | |
| SCHEMBL5092450 | 0.88 | AR (0.65) | ARCTSBGAAALDH1A1L3MBTL1 | |
| SCHEMBL4037420 | 0.88 | AR (0.65) | ARCTSBGAAALDH1A1L3MBTL1 | |
| SCHEMBL6375514 | 0.88 | AR (0.65) | ARCTSBGAAALDH1A1L3MBTL1 | |
| SCHEMBL5099264 | 0.88 | AR (0.65) | ARCTSBGAAALDH1A1L3MBTL1 | |
| SCHEMBL4039836 | 0.88 | AR (0.65) | ARCTSBGAAALDH1A1L3MBTL1 | |
| SCHEMBL5093823 | 0.86 | AR (0.68) | ARAGTR2 | |
| SCHEMBL4038981 | 0.86 | AR (0.63) | ARCTSBGAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-22 | — | — | US | claimed |
| EP-1299385-A2 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2003-04-09 | — | — | EP | claimed |
| WO-2002000653-A2 | FUSED CYCLIC COMPOUNDS AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | AR 43/4885CTSB 4427/4885GAA 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.